Medicare Transaction Facilitator: Track Every MFP Refund Still Owed

Why the gap shows in the bank before it shows on a report

On a selected drug, the pharmacy buys the stock at its usual cost and pays the wholesaler on its usual terms. The plan pays the claim at no more than the MFP plus the dispensing fee, and for a clean electronic claim from a network pharmacy (other than mail-order and long-term care) a Part D plan must pay within 14 days of receiving it (42 CFR 423.520). The difference arrives later, as a manufacturer refund, through a separate system and on a separate remittance.

Nothing about that is wrong; it is how the program is built. But it means every selected-drug claim opens a small receivable that sits outside the usual claims-and-remittance routine. If nobody owns it, the first sign of a late or short refund is a thinner bank balance on the day a wholesaler payment is due.

Illustrative example: a pharmacy fills 100 selected-drug claims a month with an average estimated refund of $300. That is $30,000 a month owed by manufacturers. If refunds arrive about three weeks after the date of service, roughly three weeks of refunds, about $21,000, are outstanding on any given day before a single refund runs late. A refund that is short, missing or stuck behind a data correction adds to that figure, and nothing in the dispensing system’s daily totals will show it.

The weekly MFP refund ledger

The fix is a ledger: one line per selected-drug claim, filled from records the pharmacy already receives, and read once a week. CMS points pharmacies to two of its own tools for this: the Claims Tracking Report in the Data Module, which shows claim-level status through the refund process and how each refund amount was calculated, and the 835 electronic remittance advice, which carries the final refund amount and the adjustment codes. The ledger simply puts them side by side with the plan’s estimate.

• Date of service, the pharmacy’s prescription number, the NDC and the manufacturer.
• The estimated refund the plan returned on the claim.
• Status from the Claims Tracking Report: data received, refund authorized, refund paid, or no refund, with the pricing method code.
• The amount received on the 835, the deposit date, and any remark code.
• Days outstanding since the date of service, and the difference between estimate and amount paid.

Each week, total three numbers: refunds outstanding, refunds older than the pharmacy’s own cutoff (CMS’s 21-day average is a sensible first line to watch), and short payments. Group the old and short ones by manufacturer, because the next step depends on who owes the money.

Reading the 835: what the MFP codes say

For an independent pharmacy that receives its own payment and remittance, CMS says the facilitator sends one payment a day that includes all participating manufacturers, with each store’s NPI and each prescription identified in the usual 835 loops. If a PSAO receives payment and remittance on a central-pay basis, the payments are broken out that way instead. CMS says 835s are available up to three business days after a claim is finalized and are typically released the same day as the deposit.

CMS worked with X12 to add one claim adjustment reason code and seven remark codes for this program. Claim adjustment reason code 307 marks an adjustment to the default refund amount and always comes with a remark code. In plain terms, the remark codes CMS lists say:

• N907 and N917: no refund, or an alternative amount, because the claim was identified as 340B-eligible and the 340B ceiling price is involved.
• N908: no refund because the drug was bought at the MFP up front.
• N909: the refund was calculated by a method other than the default (wholesale acquisition cost minus MFP, times quantity).
• N910: a refund cannot be provided at this time; contact the manufacturer about eligibility.
• N911: the manufacturer cannot pay until the Part D plan sends corrected claim data to CMS.
• N918: no refund because CMS excludes claim records whose compound code marks a compounded drug.

N911 and N910 are the ones to chase, because each points to a specific party who has to act. N918 matters to compounding pharmacies: CMS excludes compounded-drug claim records from the refund process, so a compounded preparation should not sit in the ledger as money owed. That is CMS’s code text, not advice on billing compounds; the PSAO is the place to ask.

When a refund is late, short or missing

CMS sets out two routes. First, contact the manufacturer directly: each manufacturer’s MFP Effectuation Plan, readable in the Data Module under the manufacturer dashboard, says how to reach it about refund concerns. Second, submit a complaint or dispute to CMS through the MTF Help Desk portal. CMS asks for a detailed description, supporting documents, and accurate NPIs, internal claim numbers and selected drugs, and says it may not report the outcome of a particular complaint back to the pharmacy. The ledger is what makes either route fast: it already holds the claim, the estimate, the amount paid and the days outstanding.

Some delays are on the pharmacy’s side of the setup, and CMS lists them plainly. Enrolling in the Data Module is, in CMS’s words, the single most important action a pharmacy can take to receive refunds quickly. Electronic payment is faster than paper checks. Bank details must be current. Payment and remittance should not be sent to different third-party vendors. And each user has to log in to the Data Module at least every 60 days to keep the CMS login active. A Part D plan adjudicates the claim whether or not the pharmacy is enrolled, so a missing enrollment shows up only as refunds that never arrive.

Are you losing money on MFP drugs like Jardiance and Xarelto?

A pharmacy loses money on a selected-drug claim when what the claim pays, plus the manufacturer refund, comes to less than what the pharmacy paid for the drug and what it costs to fill. That happens in three places: the pharmacy paid more than the wholesale acquisition cost (WAC), the refund came in short or not at all, or the plan’s payment and dispensing fee do not cover the cost of the fill. Jardiance and Xarelto are two of the ten first-cycle selected drugs. CMS’s 2024 fact sheet lists a negotiated price of $197 for a 30-day supply in 2026 for each, against 2023 list prices of $573 and $517, a 66% and 62% discount. At those list prices, the larger part of what the drug costs arrives as a refund, not as the plan payment.

The default refund is built on WAC, not on the pharmacy’s invoice. In its September 2025 final guidance, CMS says that, absent information indicating otherwise, it will consider WAC “an appropriate proxy” for a pharmacy’s acquisition cost and the default refund as meeting the manufacturer’s obligation. A manufacturer can still pay a different amount, and a pharmacy can work with it on a refund based on actual acquisition cost. For example, a pharmacy that paid $10 more than WAC for a 30-day fill and received the default refund would be $10 short on that claim before the dispensing fee is counted. On fees, CMS says it is not setting dispensing fee requirements for selected drugs at this time; it will monitor complaints and audits and encourages plans to ensure adequate and fair compensation, so the fee is set by the network contract. Not legal advice.

To know whether the pharmacy is losing money, check each selected-drug claim against four numbers next to the weekly ledger:

• Invoice cost against WAC on the date of service. If the invoice is higher, the default refund does not close the gap. Raise it with the manufacturer through the contact route in its MFP Effectuation Plan; if that fails, use CMS’s complaint process, where CMS says it considers the pharmacy’s invoice amount, if available, in deciding whether the MFP was made available.
• Refund received against the plan’s estimate, read with the remark code on the 835 (see the codes above).
• Plan payment and dispensing fee against the pharmacy’s cost to fill. With no CMS dispensing fee requirement for selected drugs, a fee that does not cover the work is a contract question to take to the PSAO.
• Days outstanding. Even a correct refund arrives separately from the plan payment and on its own clock, which costs cash, not margin.

The cash-flow self-identification, and what to do with it

When a pharmacy enrolls, the Data Module lets it self-identify as anticipating material cash flow issues, as defined in CMS’s final guidance. CMS’s examples include sole proprietor rural or urban pharmacies with a high volume of Part D prescriptions and pharmacies that rely mainly on prescription revenue. CMS passes that list to manufacturers, and each manufacturer’s MFP Effectuation Plan must describe its approach to mitigating those concerns.

Whether to self-identify is the owner’s decision, made with the PSAO. What each manufacturer does with it is written in that manufacturer’s plan, and the plans are readable in the Data Module; read them rather than assuming. The guidance itself is not final regulation yet: CMS published a proposed rule to codify the Negotiation Program on June 16, 2026, comments closed on August 17, 2026, and no final rule had appeared in the Federal Register as of October 17, 2026. Treat the timelines above as CMS’s current guidance, and recheck the pharmacy resources page each quarter.

For cash planning, the ledger’s outstanding total belongs on the same page as wholesaler due dates and expected plan deposits. A simple weekly table of what is due out against what is due in shows whether refunds outstanding will meet a payment date, before the payment date arrives.

When this needs no outside help

If the pharmacy is enrolled in the Data Module, receives electronic payments, reads the Claims Tracking Report against its 835s each week and knows its refunds outstanding by manufacturer, there is nothing here to hire anyone for. Keep the routine; it takes an hour a week.

Where that ledger cannot be built, or where refunds owed sit next to other money questions (claims paid below cost, fees and clawbacks matched to nothing, cash on the shelf), the Revenue Review is a read-only engagement of two weeks. It reads aggregate claims, remittance and purchasing reports, puts a monthly dollar figure on each leak, and ends in a ranked fix list and a 90-day plan. It makes no clinical, compliance or legal judgment and does not file complaints on a pharmacy’s behalf. To start smaller, book a free 20-minute call and bring the refund totals.